Teladoc Health (TDOC)
(Delayed Data from NYSE)
$13.74 USD
+0.44 (3.31%)
Updated Apr 23, 2024 04:00 PM ET
Pre-Market: $13.80 +0.06 (0.44%) 8:58 AM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Teladoc (TDOC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$20.18 | $28.00 | $16.00 | 46.87% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for Teladoc comes to $20.18. The forecasts range from a low of $16.00 to a high of $28.00. The average price target represents an increase of 46.87% from the last closing price of $13.74.
Analyst Price Targets (19)
Broker Rating
Teladoc currently has an average brokerage recommendation (ABR) of 2.52 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 23 brokerage firms. The current ABR compares to an ABR of 2.52 a month ago based on 23 recommendations.
Of the 23 recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 21.74% and 4.35% of all recommendations. A month ago, Strong Buy made up 21.74%, while Buy represented 4.35%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 17 | 17 | 17 | 17 | 16 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.52 | 2.52 | 2.52 | 2.52 | 2.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/5/2024 | Needham & Company | Ryan Macdonald | Hold | Hold |
3/8/2024 | William Blair | Ryan S Daniels | Hold | Hold |
3/6/2024 | Truist Securities | Jailendra Singh | Hold | Hold |
2/29/2024 | Cantor Fitzgerald & Co | Sarah James | Not Available | Strong Buy |
2/26/2024 | SVB Securities | Michael Cherny | Not Available | Hold |
2/21/2024 | Canaccord Genuity | Richard Close | Strong Buy | Strong Buy |
2/21/2024 | Piper Sandler | Jessica E Tassan | Strong Buy | Strong Buy |
1/17/2024 | D.A. Davidson | Gil Luria | Hold | Hold |
1/2/2024 | BTIG | David M Larsen | Not Available | Hold |
11/1/2023 | Stephens | Jeffrey Garro | Hold | Hold |
10/25/2023 | KeyBanc Capital Markets | Scott Schoenhaus | Hold | Hold |
9/18/2023 | Guggenheim Securities | Jack D Wallace | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.52 |
ABR (Last week) | 2.52 |
# of Recs in ABR | 23 |
Average Target Price | $20.18 |
LT Growth Rate | NA |
Industry | Medical Services |
Industry Rank by ABR | 91 of 252 |
Current Quarter EPS Est: | -0.47 |